SLB1122168 formic

• CAT Number: I040826
• Molecular Formula: C23H37N3O3
• Molecular Weight: 403.56
• Purity: ≥95%
• Synonyms: 6-decyl-N-[[(3S)-pyrrolidin-3-yl]methyl]-1,3-benzoxazol-2-amine;formic acid
• IUPAC Name: 5-decyl-N-[[(3R)-pyrrolidin-3-yl]methyl]-1,3-benzoxazol-2-amine;formic acid
• InChI: InChI=1S/C22H35N3O.CH2O2/c1-2-3-4-5-6-7-8-9-10-18-11-12-20-21(15-18)26-22(25-20)24-17-19-13-14-23-16-19;2-1-3/h11-12,15,19,23H,2-10,13-14,16-17H2,1H3,(H,24,25);1H,(H,2,3)/t19-;/m0./s1
• InChIKey: NCROFXPTZAVBIP-FYZYNONXSA-N
• SMILES: CCCCCCCCCCC1=CC2=C(C=C1)N=C(O2)NCC3CCNC3.C(=O)O

​SLB1122168 formic(CAT: I040826) is a potent inhibitor of the sphingosine-1-phosphate (S1P) transporter Spinster homolog 2 (Spns2), exhibiting an IC50 of 94 nM. By targeting Spns2, SLB1122168 formic effectively reduces circulating lymphocyte counts without altering plasma S1P concentrations, making it a valuable tool for researching immune cell trafficking and related diseases. In animal studies, a single intraperitoneal administration of 10 mg/kg in rats achieved a peak plasma concentration of 4 μM at 2 hours post-dose, maintaining levels at or above 1 μM for 24 hours, with a half-life of 8 hours. These pharmacokinetic properties support its potential use in preclinical research focused on conditions such as ulcerative colitis and multiple sclerosis.